Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.


Journal Article

BACKGROUND: Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) is an outcome study investigating aggressive antihypertensive combination treatment. It has achieved a larger fraction of overall patients with blood pressure (BP) <140/90 mmHg (73.3%) and diabetic patients <130/80 mmHg (43.3%) at 12 months of follow-up than any other large outcomes trial. We have analyzed baseline predictors of BPs and BP control at 12 months. METHODS: Blinded baseline and 12-month BP was available in 10,173 patients of whom 6132 had diabetes. Univariate and multivariate logistic regression models were used for BP control at 12 months; simple and multiple regression models were used for absolute BP value at 12 months. A stepwise procedure was used to select significant predictors in multivariate analyses. RESULTS: Mean (SD) BP fell from 145.5/80.2 mmHg (18.2/10.7 mmHg) at randomization to 132.7/74.7 mmHg (16/9.6 mmHg) at 12 months. The main baseline predictors of achieving BP control were region (USA), Caucasian race and taking lipid-lowering drugs. The predictors of uncontrolled BP were higher baseline systolic BP values, more previous antihypertensive medications, proteinuria and previous thiazide use. CONCLUSION: Patients in the USA, Caucasians and patients taking lipid-lowering therapy were most likely to reach BP targets with combination therapy. Strong predictors of uncontrolled hypertension were more severe hypertension, an established need for more antihypertensive drugs and target organ damage.

Full Text

Cited Authors

  • Kjeldsen, SE; Jamerson, KA; Bakris, GL; Pitt, B; Dahlöf, B; Velazquez, EJ; Gupte, J; Staikos, L; Hua, TA; Shi, V; Hester, A; Tuomilehto, J; Ostergren, J; Ibsen, H; Weber, M; Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension Investigators,

Published Date

  • January 2008

Published In

Volume / Issue

  • 17 / 1

Start / End Page

  • 7 - 17

PubMed ID

  • 18568687

Pubmed Central ID

  • 18568687

Electronic International Standard Serial Number (EISSN)

  • 1651-1999

International Standard Serial Number (ISSN)

  • 0803-7051

Digital Object Identifier (DOI)

  • 10.1080/08037050801972857


  • eng